Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $18
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $12 to $18.
Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $12 to $18.